slides · global inventory
Traction
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 10,471
Current window 5,401-5,430
Pages 350
Rows per page 30
Slide type
5,401-5,430 of 10,471
26
Data presented across three line charts comparing 'All HS Patients' vs 'Moderate to Severe' subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
27
The charts demonstrate a shift from higher severity scores (orange/red) to lower severity scores (blue/black) over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
36
The slide presents two charts: a tumor growth inhibition curve and a PK/PD correlation chart showing drug concentration vs. target degradation over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
39
Includes a disclaimer/footnote regarding patient population and MYD88 mutation status.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
43
The slide presents two distinct charts: a tumor volume growth curve and a PK/PD concentration-time profile.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
47
The slide presents clinical trial results for KT-333, comparing degradation percentages across three dose levels (DL1, DL2, DL3) over two cycles.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
48
Includes bar charts for SAA/CRP reduction, a longitudinal line chart for biomarker changes, and a scatter plot showing correlation between STAT3 and SOCS3 changes.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
49
DL1-3 refers to dose levels 1-3. PK = Pharmacokinetics, PD = Pharmacodynamics, DLT = Dose-Limiting Toxicity, SAE = Serious Adverse Event.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
54
Data presented as tumor volume growth curves and Kaplan-Meier survival plots.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
56
Shows two distinct experiments: DFAM-6855 (Whole Blood) and MOLM-13 (Tumor Volume).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
10
The slide uses a 3-column layout to categorize achievements by strategic channel.Mainz Biomed NV | Investor Presentation Deck | 25 slides · Mainz Biomed
Pitch deck Investor relations Beat · Traction1 hit
15
Includes a citation to a published study in the journal 'Cancers' and collaboration with Université de Sherbrooke.Mainz Biomed NV | Investor Presentation Deck | 25 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
14
Data source: Holze, Gasser et al. 2022. Biological Psychiatry.MindMed | Investor Presentation Deck | 36 slides · MindMed
Pitch deck Investor relations 1 hit
22
The chart shows a comparison between Placebo and MDMA at 1 month and 6 months, indicating sustained improvement.MindMed | Investor Presentation Deck | 36 slides · MindMed
Pitch deck Investor relations 1 hit
25
The slide uses two distinct chart types (bar and line) to show efficacy across different translational markers.MindMed | Investor Presentation Deck | 36 slides · MindMed
Pitch deck Investor relations 1 hit
13
Includes a bar chart of motor performance and visual evidence of motor neuron recovery.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
The slide uses a comparative clinical trial analysis against a historical control database (PRO-ACT).NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
Data shows p-values of 0.005 and <0.001 for treated groups, indicating significant biomarker reduction.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
18
The slide uses a process-flow diagram to link trial results to the next phase of development.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
31
The chart shows a negative correlation trend line between TDP-43 change and ALSFRS-R slope.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
09
Slide 9 of the deck.Nexters | Investor Presentation Deck | 19 slides · GDEV
Pitch deck Investor relations Loop · Voice Of Customer1 hit
12
The slide uses a broken axis for the Total Comprehensive Income/Loss chart to accommodate the negative 2021 value.Nexters | Investor Presentation Deck | 19 slides · GDEV
Pitch deck Investor relations Beat · FinancialsLoop · Benchmark Gap1 hit
14
The slide uses bar charts with percentage change annotations to highlight year-over-year performance.Nexters | Investor Presentation Deck | 19 slides · GDEV
Pitch deck Investor relations Beat · FinancialsLoop · Benchmark Gap1 hit
21
The slide highlights operational growth despite external market headwinds.Proterra | Investor Presentation Deck | 25 slides · Proterra
Pitch deck Investor relations Beat · Traction1 hit
22
The chart uses a stacked bar format with a gradient fill.Proterra | Investor Presentation Deck | 25 slides · Proterra
Pitch deck Investor relations Beat · Traction1 hit
24
Proterra | Investor Presentation Deck | 25 slidesProterra | Investor Presentation Deck | 25 slides · Proterra
Pitch deck Investor relations 1 hit
09
The slide uses a combination of a bar chart for asset growth and a table for market ranking.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations Loop · Golden Circle1 hit
11
The chart shows a clear transition from ICE to EV production over time, culminating in a 2023 target of zero ICE production.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations Loop · Golden Circle1 hit
16
The slide uses a grid of big numbers to highlight scale and momentum.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
04
Vivid Seats | Investor Presentation Deck | 24 slidesVivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · Traction1 hit